M VAYRYNEN
Overview
Explore the profile of M VAYRYNEN including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nieminen P, Lopponen H, VAYRYNEN M, Tervonen A, Tolonen U
Int J Pediatr Otorhinolaryngol
. 2000 Mar;
52(1):53-60.
PMID: 10699240
Objective: Snoring and the sleep apnea syndrome (OSAS) in children are usually caused by adenotonsillar hypertrophy, which may affect air escape into the nose and nasal resonance. A microcomputer-based system...
2.
Syrjanen K, Nurmi T, Mantyjarvi R, Ilonen J, Syrjanen S, Surcel H, et al.
Cytopathology
. 1996 Apr;
7(2):99-107.
PMID: 9074659
Certain genotypes of HPV have been recently implicated in the etiology of carcinoma of the uterine cervix. In order to determine whether HLA antigen-controlled immunoregulatory functions have a role in...
3.
Uhari M, Kokkonen J, Nuutinen M, Vainionpaa L, Rantala H, Lautala P, et al.
JAMA
. 1994 Apr;
271(13):1049-51.
PMID: 8139064
Objective: To evaluate the prevalence of physical and psychological mistreatment of medical students at two medical schools in Finland. Study Design And Setting: To enable comparison between Finnish and American...
4.
Maenpaa J, Kivinen S, Raisanen I, Sipila P, VAYRYNEN M, Grohn P
Ann Chir Gynaecol Suppl
. 1994 Jan;
208:25-7.
PMID: 8092765
In a non-randomized clinical trial, combined intraperitoneal therapy with recombinant interferon alpha-2b (20-50 MU) and mitoxantrone (20-50 mg) was studied for recurrent ovarian cancer with ascites. Altogether 19 patients were...
5.
Kataja V, Syrjanen S, Yliskoski M, Hippelinen M, VAYRYNEN M, Saarikoski S, et al.
Am J Epidemiol
. 1993 Nov;
138(9):735-45.
PMID: 8237988
As a part of the long-term prospective follow-up study conducted for women with genital human papillomavirus (HPV) infections in Kuopio University Hospital, Finland, since 1981, a case-control study was designed...
6.
Lahtinen T, Tenhunen M, VAYRYNEN M
Radiother Oncol
. 1993 Aug;
28(2):174-6.
PMID: 8248560
The absorbed doses in the reference points of the rectum and bladder defined by ICRU report 38 for reporting intracavitary radiotherapy were compared with the calculated maximum doses of these...
7.
Tervahauta A, Syrjanen S, VAYRYNEN M, Saastamoinen J, Syrjanen K
Anticancer Res
. 1993 Jul;
13(4):1107-11.
PMID: 8394670
The E6 protein of the high-risk human papillomavirus (HPV) types 16 and 18 is capable of complexing with the wild-type p53 tumor suppressor gene product, leading to loss of the...
8.
Mervaala E, Alhainen K, Helkala E, Partanen J, Jousmaki V, VAYRYNEN M, et al.
Behav Brain Res
. 1993 May;
55(1):85-91.
PMID: 8101086
We studied the electrophysiological and neuropsychological effects of acute modulation of central noradrenergic (NA) transmission using a specific alpha 2-antagonist atipamezole (ATI) in sic healthy volunteers. ATI had effects on...
9.
Ji H, Yliskoski M, VAYRYNEN M, Hippelainen M, Syrjanen S, Syrjanen K
Int J Gynaecol Obstet
. 1991 Dec;
36(4):291-300.
PMID: 1684763
A long-term prospective follow-up program has been conducted for genital human papillomavirus (HPV) infections in 532 women in Kuopio since 1981. By regular examinations (at 6-month intervals) using colposcopy, cytology...
10.
Hallikainen H, Partanen J, VAYRYNEN M
Duodecim
. 1991 Jan;
107(23-24):1950-8.
PMID: 1366103
No abstract available.